Showing 13,841 - 13,860 results of 24,096 for search '(( 50 ((nn decrease) OR (mean decrease)) ) OR ( 100 ((teer decrease) OR (a decrease)) ))', query time: 0.70s Refine Results
  1. 13841

    Image_3_Global burden of lower respiratory infections during the last three decades.PDF by Saeid Safiri (3713035)

    Published 2023
    “…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”
  2. 13842

    Presentation_1_Global burden of lower respiratory infections during the last three decades.PDF by Saeid Safiri (3713035)

    Published 2023
    “…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”
  3. 13843

    Image_12_Global burden of lower respiratory infections during the last three decades.PDF by Saeid Safiri (3713035)

    Published 2023
    “…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”
  4. 13844

    Image_10_Global burden of lower respiratory infections during the last three decades.PDF by Saeid Safiri (3713035)

    Published 2023
    “…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”
  5. 13845

    Presentation_3_Global burden of lower respiratory infections during the last three decades.PDF by Saeid Safiri (3713035)

    Published 2023
    “…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”
  6. 13846

    Table_4_Global burden of lower respiratory infections during the last three decades.DOC by Saeid Safiri (3713035)

    Published 2023
    “…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”
  7. 13847

    Image_2_Global burden of lower respiratory infections during the last three decades.PDF by Saeid Safiri (3713035)

    Published 2023
    “…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”
  8. 13848

    Image_4_Global burden of lower respiratory infections during the last three decades.PDF by Saeid Safiri (3713035)

    Published 2023
    “…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”
  9. 13849

    Image_6_Global burden of lower respiratory infections during the last three decades.PDF by Saeid Safiri (3713035)

    Published 2023
    “…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”
  10. 13850

    Image_7_Global burden of lower respiratory infections during the last three decades.PDF by Saeid Safiri (3713035)

    Published 2023
    “…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”
  11. 13851

    Image_13_Global burden of lower respiratory infections during the last three decades.PDF by Saeid Safiri (3713035)

    Published 2023
    “…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”
  12. 13852

    Table1_Meta-Analysis Approach to Measure the Effect of Integrated Nutrient Management on Crop Performance, Microbial Activity, and Carbon Stocks in Indian Soils.docx by Rajeev Padbhushan (11556871)

    Published 2021
    “…<p>Cereal crop production gains under conventional agricultural systems in India have been declining in recent years because of inadequate management practices, creating a considerable concern. These activities were shown to deplete soil organic matter stocks, resulting in a decrease in microbial activity and soil organic carbon (SOC) content. …”
  13. 13853

    Table_2_Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types.xlsx by Tianmeng Yan (16682754)

    Published 2023
    “…Compared to systemic corticosteroid alone, dupilumab with or without systemic corticosteroid was similarly efficacious in clinical remission at week4 (complete remission plus partial remission: 100%) and week24 (complete remission plus partial remission:100%), but allowing significant decreases in the cumulative doses of corticosteroids with reducing the incidence of adverse events. …”
  14. 13854

    NTS_QECH by Catherine Wilson (8586315)

    Published 2022
    “…Estimated minimum incidence of iNTS disease decreased from 21/100,000 per year in 2011 to 7/100,000 per year in 2019. …”
  15. 13855

    Table_1_Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types.docx by Tianmeng Yan (16682754)

    Published 2023
    “…Compared to systemic corticosteroid alone, dupilumab with or without systemic corticosteroid was similarly efficacious in clinical remission at week4 (complete remission plus partial remission: 100%) and week24 (complete remission plus partial remission:100%), but allowing significant decreases in the cumulative doses of corticosteroids with reducing the incidence of adverse events. …”
  16. 13856

    Table_3_Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types.xlsx by Tianmeng Yan (16682754)

    Published 2023
    “…Compared to systemic corticosteroid alone, dupilumab with or without systemic corticosteroid was similarly efficacious in clinical remission at week4 (complete remission plus partial remission: 100%) and week24 (complete remission plus partial remission:100%), but allowing significant decreases in the cumulative doses of corticosteroids with reducing the incidence of adverse events. …”
  17. 13857

    Table_1_Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types.docx by Tianmeng Yan (16682754)

    Published 2023
    “…Compared to systemic corticosteroid alone, dupilumab with or without systemic corticosteroid was similarly efficacious in clinical remission at week4 (complete remission plus partial remission: 100%) and week24 (complete remission plus partial remission:100%), but allowing significant decreases in the cumulative doses of corticosteroids with reducing the incidence of adverse events. …”
  18. 13858

    Increased CN inhibition leads to reduced STO frequency and to more CSpk frequency. by Elías M. Fernández Santoro (22470299)

    Published 2025
    “…<p>(A) After Plasticity difference for SSpks is significant across coupled cases for the Upbound zone (t = 4.51, p < 0.001; two-sample Student’s t-test; n = 100) and for coupled case across zones (t = -5.36, p < 0.001; two-sample Student’s t-test; n = 100). …”
  19. 13859

    DataSheet_1_Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types.docx by Tianmeng Yan (16682754)

    Published 2023
    “…Compared to systemic corticosteroid alone, dupilumab with or without systemic corticosteroid was similarly efficacious in clinical remission at week4 (complete remission plus partial remission: 100%) and week24 (complete remission plus partial remission:100%), but allowing significant decreases in the cumulative doses of corticosteroids with reducing the incidence of adverse events. …”
  20. 13860

    Table1_Changes in the global burden of foreign body aspiration among under-5 children from 1990 to 2019.xls by Yuying Wu (647826)

    Published 2023
    “…Many European countries (such as Italy, Netherlands, Iceland, etc.) showed a high incidence rate, but did not cause a large disease burden (DALYs all less than 200 per 100,000). …”